FDA Approves Depemokimab for Severe Asthma: New Eosinophilic Treatment Option

Executive Brief

News Report

The News: FDA approves depemokimab for severe asthma treatment.
Clinical Win: New biologic offers hope for eosinophilic asthma patients.
Target Specialty: Pulmonology

Key Data at a Glance

Approval Date: December 16, 2025
Target Population: Severe asthma with eosinophilic phenotype
Administration: Subcutaneous injection

The FDA has approved depemokimab for the treatment of severe asthma characterized by an eosinophilic phenotype. This new biologic therapy is significant for healthcare providers managing patients with severe asthma, particularly those who have not responded adequately to existing treatments. The approval was announced on December 16, 2025.

Clinical Context

Asthma is a chronic respiratory condition affecting millions worldwide, characterized by inflammation and narrowing of the airways, leading to symptoms such as wheezing, coughing, and difficulty breathing. It is a major public health concern, with an estimated 363 million people affected globally as of 2023, resulting in approximately 442,000 deaths annually [2]. Current treatment options for severe asthma include inhaled corticosteroids and biologics targeting specific inflammatory pathways. However, many patients remain uncontrolled despite these therapies, highlighting the need for new treatment options. The introduction of biologics like depemokimab, mepolizumab, benralizumab, and dupilumab represents a shift towards more personalized asthma management, particularly for those with eosinophilic asthma, a subtype characterized by high eosinophil levels and frequent exacerbations.

Key Findings

The FDA approved depemokimab for severe asthma characterized by an eosinophilic phenotype as an add-on maintenance therapy on December 16, 2025 [7].

Depemokimab is administered via subcutaneous injection, with dosing recommendations based on individual patient needs and treatment response [7].

The approval is based on clinical trial data demonstrating significant improvements in asthma control and reductions in exacerbation rates compared to placebo [7].

Other biologics for severe asthma include mepolizumab, benralizumab, and dupilumab, which target different pathways in the inflammatory process, providing multiple options for clinicians to tailor treatment to individual patient profiles [1].

What This Means for Clinical Practice

The approval of depemokimab provides an additional tool for clinicians managing severe asthma, particularly in patients with an eosinophilic phenotype who have not achieved adequate control with existing therapies. This biologic therapy offers a new mechanism of action, potentially improving asthma control and reducing the frequency of exacerbations. Clinicians should consider patient-specific factors, such as eosinophil levels and previous treatment responses, when selecting among available biologics. The introduction of depemokimab may also influence treatment guidelines and reimbursement strategies, necessitating ongoing education and adaptation in clinical practice to optimize patient outcomes.

The landscape of severe asthma management continues to evolve, and understanding the nuances of each biologic will be crucial for effective patient care. How these new treatment options will be integrated into existing guidelines and clinical pathways remains to be seen.

Clinical Perspective

Workflow: Clinicians will need to evaluate eosinophil levels and treatment history when prescribing depemokimab.

Economics: The introduction of depemokimab may impact healthcare costs and insurance coverage for severe asthma treatments.

Patient Outcomes: Improved asthma control and reduced exacerbations are expected with the use of depemokimab in appropriate patients.

Dr. Nikhil Chatterjee, Pulmonology

FDA Approves Depemokimab for Severe Asthma: New Eosinophilic Treatment Option

Executive Brief

Key Data at a Glance

Clinical Context

Key Findings

What This Means for Clinical Practice

Clinical Perspective

References

Get weekly drug updates for Pulmonology in your inbox.

Related Drug Updates

FDA Approves Depemokimab for Severe Asthma: Once-Yearly Injection for Eosinophilic Phenotype

FDA Approves Depemokimab for Severe Asthma: Eosinophilic Phenotype Treatment

Severe Asthma Biologics: Mepolizumab, Benralizumab, Dupilumab, Tezepelumab, and Depemokimab Insights for 2025

Verified HCP Portal